2. Neratinib causes significant gastrointestinal toxicity. Diarrhoea affects most patients, is severe in a high proportion, and can be expected to affect quality of life. Based on available data from study 6201, it is uncertain at this time whether the diarrhoea can be adequately managed by prophylactic anti-diarrhoeals. The very high rate of early discontinuations from this trial despite intensive loperamide prophylaxis is of concern. It is also unclear to what extent diarrhoea may improve over time for the individual patient who decides to remain on treatment after experiencing severe diarrhoea. In routine clinical practice, there may be an even greater rate of treatment discontinuations due to diarrhoea, leading to a reduction in efficacy. In the presence of a robustly demonstrated important clinical benefit the side effect profile might be considered acceptable, but is of major concern in the context of the deficiencies in the demonstration of efficacy.
2. Neratinib causes significant gastrointestinal toxicity. Diarrhoea affects most patients, is severe in a high proportion, and can be expected to affect quality of life. Based on available data from study 6201, it is uncertain at this time whether the diarrhoea can be adequately managed by prophylactic anti-diarrhoeals. The very high rate of early discontinuations from this trial despite intensive loperamide prophylaxis is of concern. It is also unclear to what extent diarrhoea may improve over time for the individual patient who decides to remain on treatment after experiencing severe diarrhoea. In routine clinical practice, there may be an even greater rate of treatment discontinuations due to diarrhoea, leading to a reduction in efficacy. In the presence of a robustly demonstrated important clinical benefit the side effect profile might be considered acceptable, but is of major concern in the context of the deficiencies in the demonstration of efficacy.
正在翻译中..